ImmunoCellular Therapeutics, Ltd. has announced that recently completed proof-of-principle studies demonstrate efficacy of its cancer stem cell vaccine technology in treating glioblastoma, a form of brain cancer, in preclinical animal models.
The company is planning to submit an Investigational New Drug (IND) application to the FDA later this year to commence a Phase I clinical trial for its cancer stem cell vaccine product, ICT-111, to treat glioblastoma. The company’s cancer stem cell vaccine technology also could be applicable for multiple other cancers.
“We are excited about the data we have observed from the preclinical studies demonstrating a highly specific and potent immune response against cancer stem cells, as well as a survival advantage in the animals tested in preclinical studies,” stated Manish Singh, Ph.D., president and chief executive officer of IMUC.
“We are pleased to see a growing interest in the area of cancer stem cell technologies, an example of which is an article in the April 2008 issue of Nature Biotechnology that named ICT-111 as one of eight products under development targeting cancer stem cells for various types of cancer.”